

**Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee (ODAC) Meeting**
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD

July 14, 2011

DRAFT MEETING ROSTER

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Deborah Armstrong, M.D.

Associate Professor of Oncology
Johns Hopkins Kimmel Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland 21231

Ralph Freedman, M.D., Ph.D.

Clinical Professor
Department of Gynecologic Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas 77230

William Kelly, D.O.

Professor of Medical Oncology and Urology
Thomas Jefferson University
Philadelphia, Pennsylvania 19107

Mikkael Sekeres, M.D., M.S.

Associate Professor of Medicine
Staff
Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, Ohio 44195

Julie M. Vose, M.D.

Neumann M. and Mildred E. Harris Professor
Chief, Division of Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska 68198

Wyndham Wilson, M.D., Ph.D.

(Chairperson)
Chief, Lymphoma Therapeutics Section
Metabolism Branch
Center for Cancer Research
National Cancer Institute
Rockville, Maryland 20892

Antoinette Wozniak, M.D., F.A.C.P.

Professor, Department of Oncology
Wayne State University School of Medicine and
Karmanos Cancer Institute
Detroit, Michigan 48201

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Gregory Curt, M.D.

(Industry Representative)

U.S. Medical Science Lead, Emerging Products
AstraZeneca Oncology
Garrett Park, Maryland 20896

**Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee (ODAC) Meeting**
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD

July 14, 2011

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Melanie Bilkis
(Patient Representative – Morning Session
Only)
New York, New York 10023

David Harrington, Ph.D.
Professor of Biostatistics
Department of Biostatistics
Harvard School of Public Health
Boston, Massachusetts 02215

Virginia Mason, R.N.
(Acting Consumer Representative)
Executive Director
Inflammatory Breast Cancer Research
Foundation
West Lafayette, Indiana 47906

Raymond McGlamery
(Patient Representative – Afternoon Session
Only)
Austin, Texas 78733

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, M.D.
Director
Office of Oncology Drug Products (OODP),
Office of New Drugs (OND), CDER, FDA

Ann Farrell, M.D.
Director
Division of Hematology Products (DHP),
OODP, OND, CDER, FDA

Virginia Kwitkowski, R.N., M.S.
Medical Team Leader
DHP, OODP, OND, CDER, FDA

Angelo DeClaro, M.D.
Medical Officer
DHP, OODP, OND, CDER, FDA

Karen McGinn, MSN, CRNP
Medical Officer
DHP, OODP, OND, CDER, FDA